Autres langues Tempest Therapeutics, Inc.

Actions

TPST

US87978U1088

Temps réel estimé Cboe BZX Autres places de cotation 16:12:55 29/04/2024			Varia. 5j.	Varia. 1 janv.
3,6 ^USD	+1,69 %		+10,28 %	-18,80 %

09/04	Tempest Therapeutics, Inc. présente de nouvelles données précliniques pour le TPST-1120 dans le RCC lors de la réunion annuelle de l'AACR	CI
04/04	Tempest Therapeutics, Inc. annonce la publication des données positives de l'essai de phase 1 du TPST-1120 chez des patients atteints de tumeurs solides avancées dans le Journal of Cancer Research Communications	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	26/04
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting	10/04
Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting	09/04
Tempest Therapeutics, Inc. Reports New Preclinical Data for TPST-1120 in RCC At the AACR Annual Meeting	09/04
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications	04/04
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications	04/04
Tempest Therapeutics, Inc. Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications	04/04
Tempest Therapeutics : Corporate Presentation - April 2024	29/03
Tempest Therapeutics : Corporate Presentation - March 2024	22/03
Tempest Reports Year End 2023 Financial Results and Provides Business Update	20/03
Tempest Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19/03
Tempest Reports Year End 2023 Financial Results and Provides Business Update	19/03
Tempest Therapeutics : Reports Year End 2023 Financial Results and Provides Business Update - Form 8-K	19/03
Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)	14/03
Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types	12/03
Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types	12/03
Tempest Therapeutics, Inc. Presents New Data At the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-Tumor Activity of TPST-1120 in Multiple Cancer Types	12/03
Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting	05/03
Tempest to Present at the 44th Annual TD Cowen Healthcare Conference	26/02
Tempest to Present at the 44th Annual TD Cowen Healthcare Conference	26/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Tempest Therapeutics, Inc.

Actions

TPST

US87978U1088

Autres langues

Filtres